Developer docs
API playgroundTry for free, no card

Search company profiles

Menarini Group

Full company profile

uuid0008qqb

Namestring
Menarini Group
Legal namestring
A. Menarini Industrie Farmaceutiche Riunite S.r.l.
Websiteurl
menarini.com
Company typeenum
Private
Founded yearint
1886
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
10,001+
akta.pro rankint
HeadquartersFirenze, Italy
HQ citystring
Firenze
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, oncology therapeutics, consumer healthcare, clinical diagnostics, biopharmaceutical manufacturing
Industry1 code
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Products
TypeOne Time License
Description

Revenue from prescription pharmaceutical products across multiple therapeutic areas including oncology, cardiometabolic, anti-infectives, respiratory, gastrointestinal, pain, and dermatology

globenewswire.com
2Licensing and Royalties
TypeLicensing Royalties
Description

Revenue from licensing agreements including selinexor (global rights outside US), obicetrapib (European rights), and AI-discovered drug candidates

prnewswire.com
3Diagnostics
TypeOne Time License
Description

Revenue from professional diagnostics and advanced diagnostics including prenatal testing and rare cell analysis

globenewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1ORSERDU
Description

Brand name for elacestrant, an oral endocrine therapy for ER+/HER2- metastatic breast cancer

menarini.com
+4 more records
Core offering1 text field

Menarini Group is a fully integrated privately owned pharmaceutical company that develops, manufactures, and commercializes prescription medicines, consumer healthcare (OTC) products, oncology therapeutics, diagnostics, and dermatology/aesthetic medicine products across more than 130 countries. Its core revenue drivers are prescription pharmaceuticals spanning anti-infectives, cardiometabolic, respiratory, gastrointestinal, pain, men's health, plus a growing oncology franchise centered on elacestrant (ORSERDU®), tagraxofusp, and the licensed products selinexor and obicetrapib. The company also sells professional and advanced diagnostics and prenatal testing through its diagnostics business, and OTC products through its consumer healthcare division.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 49.8% spleen volume reduction (SVR35) at week 24 with selinexor-ruxolitinib combination vs 28% for ruxolitinib monotherapy in myelofibrosis patients
+2 more records
Product overview1 text field

Menarini Group is a fully integrated privately owned pharmaceutical company operating across five core business areas: Pharmaceuticals (prescription medicines in anti-infectives, cardiometabolic, respiratory, gastrointestinal, pain, and men's health), Consumer Healthcare (OTC products including analgesics, cough/cold/allergy, and supplements), Oncology (including Stemline Therapeutics subsidiary with treatments for breast cancer, hematologic malignancies, and solid tumors), Diagnostics (professional, advanced, and prenatal testing), and Dermatology/Aesthetic Medicine (Relife brand). Key products include ORSERDU® (elacestrant) for ER+/HER2- metastatic breast cancer, Tagraxofusp for BPDCN, licensed products obicetrapib for cholesterol and selinexor for myelofibrosis, and pipeline assets including AI-discovered MEN2501. The company reported approximately €4.9 billion in 2025 revenue with 6.2% growth, investing in oncology and AI-enabled drug discovery through partnerships with Insilico Medicine and others.

Product and service8 records
1Elacestrant (ORSERDU®)
CategoryOncology Pharmaceuticals
Description

Oral selective estrogen receptor degrader (SERD) for the treatment of ER+/HER2- metastatic breast cancer, positioned as a backbone endocrine therapy for combination treatment. Marketed as ORSERDU®.

2Tagraxofusp
CategoryOncology Pharmaceuticals
Description

CD123-targeted therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and hematologic malignancies, commercialized through Menarini's wholly-owned subsidiary Stemline Therapeutics.

3Selinexor (XPOVIO®)
CategoryOncology Pharmaceuticals (Licensed)
Description

Selective inhibitor of nuclear export (SINE) compound (XPO1 inhibitor). Menarini holds global licensing rights outside the U.S. for myelofibrosis and other indications, including combination therapy with ruxolitinib.

4Obicetrapib
CategoryCardiometabolic Pharmaceuticals (Licensed)
Description

CETP inhibitor for lowering LDL-C in patients with hypercholesterolemia. European commercialization rights exclusively licensed to Menarini Group from NewAmsterdam Pharma.

5MEN2501
CategoryOncology Pipeline (Licensed)
Description

Differentiated small molecule KIF18A inhibitor for chromosomally unstable solid tumors, AI-designed using Insilico Medicine's generative AI engine and licensed to Stemline Therapeutics. Currently in Phase 1 clinical trials.

6Consumer Healthcare Portfolio
CategoryConsumer Healthcare (OTC)
Description

Over-the-counter (OTC) consumer healthcare products including analgesics, cough/cold/allergy remedies, gastrointestinals, lifestyle OTCs, and vitamins/minerals/supplements sold to retail and consumer markets.

7Diagnostics Portfolio
CategoryDiagnostics
Description

Professional diagnostics for clinical settings, advanced diagnostics including rare cell analysis for personalized medicine, and prenatal testing services sold to healthcare institutions and laboratories.

8Relife Dermatology and Aesthetic Medicine
CategoryDermatology and Aesthetic Medicine
Description

Dermatology and aesthetic medicine brand under Menarini, focused on skin health and aesthetic treatments (tagline: 'My skin says how I feel').

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

AI-driven drug discovery collaboration where Insilico Medicine designed MEN2501 (KIF18A inhibitor) using its generative AI engine. Menarini's subsidiary Stemline Therapeutics holds the license. The combined value of agreements exceeds USD 550 million, including milestone payments of USD 3 million (July 2025 after IND approval) and USD 5 million (after first-in-human dosing).

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-04-03
Description

Strategic partnership to help biopharmaceutical companies transition from research stage to First-In-Human clinical trials, combining preclinical expertise with CMC capabilities for integrated services including non-clinical studies, regulatory-ready data modules, and scalable manufacturing.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on selinexor for myelofibrosis treatment. Menarini Group holds global licensing rights for selinexor outside the United States. The Phase 3 SENTRY trial was conducted by Karyopharm and results were presented at EHA 2026 congress, showing statistically significant spleen volume reduction improvement with the selinexor-ruxolitinib combination.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Menarini Group holds exclusive commercialization rights for obicetrapib (CETP inhibitor) in Europe. NewAmsterdam is developing the drug for hypercholesterolaemia with EMA expected to issue regulatory decision in H2 2026.

Strategic tierCoreTypeOthers
Description

Wholly-owned subsidiary of Menarini Group focused on bringing transformational oncology treatments to cancer patients. Based in the United States, Stemline commercializes elacestrant (ORSERDU®) and tagraxofusp, and holds licenses for selinexor and MEN2501.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

German-headquartered diversified life sciences group with pharmaceuticals, consumer health, and crop science. Comparable to Menarini in European roots, diversified therapeutic portfolio, and consumer healthcare scale.

TypeBroad incumbent
Description

Swiss-headquartered global pharmaceutical leader with the largest oncology franchise in the industry, complemented by diagnostics. Comparable on oncology pipeline depth and diagnostics business overlap.

TypeDirect peer
Description

Spanish privately-listed mid-pharma focused on dermatology and specialty care. Comparable European specialty pharma with overlapping consumer health and derma/aesthetic medicine profile.

4Merck KGaA
TypeBroad incumbent
Description

German diversified science and technology company with healthcare, life science, and electronics. Comparable European mid-large pharma with oncology, neurology, and fertility therapeutic areas.

TypeDirect peer
Description

Italian privately-owned pharmaceutical group operating in respiratory, neonatology, and rare diseases. Comparable privately-held European mid-pharma with focus on specialty therapeutic areas.

TypeBroad incumbent
Description

UK global biopharma with pharmaceuticals, vaccines, and consumer healthcare. Comparable to Menarini on consumer healthcare (OTC), respiratory, and oncology overlap.

TypeDirect peer
Description

Italian-headquartered mid-cap specialty pharmaceutical company with focus on cardiovascular, urology, and rare diseases. Closely comparable to Menarini in European, family-influenced pharma operating model and therapeutic focus.

TypeBroad incumbent
Description

Israel-headquartered global pharmaceutical company with large specialty and generics franchise. Comparable on broad geographic commercial reach and diversified therapeutic portfolio.

TypeBroad incumbent
Description

UK-headquartered global biopharmaceutical company with leadership in oncology, cardiometabolic, and respiratory. Comparable on the same oncology and cardiometabolic therapeutic areas that anchor Menarini's recent launches.

TypeBroad incumbent
Description

French global pharmaceutical company with strong European presence, consumer healthcare (OTC), specialty care, and oncology pipeline. Comparable diversified European pharma with comparable revenue scale and therapeutic breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Menarini Group

Pharmaceuticalsmenarini.com

Menarini Group firmographics

Firmographics
Name
Menarini Group
Legal name
A. Menarini Industrie Farmaceutiche Riunite S.r.l.
Website
https://menarini.com
Company type
Private
Founded year
1886
Operating status
Operating
Headcount range
10,001+ employees
Ownership category
akta.pro rank

Menarini Group industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Prescription pharmaceuticals
  • Oncology therapeutics
  • Consumer healthcare
  • Clinical diagnostics
  • Biopharmaceutical manufacturing

Where Menarini Group is headquartered

Location

Headquarters

HQ city
Firenze
HQ country
Italy
HQ region
Europe

Offices7 records

Markets served

Menarini Group business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Products: Revenue from prescription pharmaceutical products across multiple therapeutic areas including oncology, cardiometabolic, anti-infectives, respiratory, gastrointestinal, pain, and dermatology
  2. Licensing and Royalties: Revenue from licensing agreements including selinexor (global rights outside US), obicetrapib (European rights), and AI-discovered drug candidates
  3. Diagnostics: Revenue from professional diagnostics and advanced diagnostics including prenatal testing and rare cell analysis

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Menarini Group product offering

Product offering

Core offering

Menarini Group is a fully integrated privately owned pharmaceutical company that develops, manufactures, and commercializes prescription medicines, consumer healthcare (OTC) products, oncology therapeutics, diagnostics, and dermatology/aesthetic medicine products across more than 130 countries. Its core revenue drivers are prescription pharmaceuticals spanning anti-infectives, cardiometabolic, respiratory, gastrointestinal, pain, men's health, plus a growing oncology franchise centered on elacestrant (ORSERDU®), tagraxofusp, and the licensed products selinexor and obicetrapib. The company also sells professional and advanced diagnostics and prenatal testing through its diagnostics business, and OTC products through its consumer healthcare division.

Product overview

Menarini Group is a fully integrated privately owned pharmaceutical company operating across five core business areas: Pharmaceuticals (prescription medicines in anti-infectives, cardiometabolic, respiratory, gastrointestinal, pain, and men's health), Consumer Healthcare (OTC products including analgesics, cough/cold/allergy, and supplements), Oncology (including Stemline Therapeutics subsidiary with treatments for breast cancer, hematologic malignancies, and solid tumors), Diagnostics (professional, advanced, and prenatal testing), and Dermatology/Aesthetic Medicine (Relife brand). Key products include ORSERDU® (elacestrant) for ER+/HER2- metastatic breast cancer, Tagraxofusp for BPDCN, licensed products obicetrapib for cholesterol and selinexor for myelofibrosis, and pipeline assets including AI-discovered MEN2501. The company reported approximately €4.9 billion in 2025 revenue with 6.2% growth, investing in oncology and AI-enabled drug discovery through partnerships with Insilico Medicine and others.

Differentiator

Problem solved

Functional benefit

Brands

  • ORSERDU: Brand name for elacestrant, an oral endocrine therapy for ER+/HER2- metastatic breast cancer
  • Stemline Therapeutics
  • Relife
  • Fair Play Menarini
  • Fondazione Menarini

Products and services

  • Elacestrant (ORSERDU®) Oral selective estrogen receptor degrader (SERD) for the treatment of ER+/HER2- metastatic breast cancer, positioned as a backbone endocrine therapy for combination treatment. Marketed as ORSERDU®.
  • Tagraxofusp CD123-targeted therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and hematologic malignancies, commercialized through Menarini's wholly-owned subsidiary Stemline Therapeutics.
  • Selinexor (XPOVIO®) Selective inhibitor of nuclear export (SINE) compound (XPO1 inhibitor). Menarini holds global licensing rights outside the U.S. for myelofibrosis and other indications, including combination therapy with ruxolitinib.
  • Obicetrapib CETP inhibitor for lowering LDL-C in patients with hypercholesterolemia. European commercialization rights exclusively licensed to Menarini Group from NewAmsterdam Pharma.
  • MEN2501 Differentiated small molecule KIF18A inhibitor for chromosomally unstable solid tumors, AI-designed using Insilico Medicine's generative AI engine and licensed to Stemline Therapeutics. Currently in Phase 1 clinical trials.
  • Consumer Healthcare Portfolio Over-the-counter (OTC) consumer healthcare products including analgesics, cough/cold/allergy remedies, gastrointestinals, lifestyle OTCs, and vitamins/minerals/supplements sold to retail and consumer markets.
  • Diagnostics Portfolio Professional diagnostics for clinical settings, advanced diagnostics including rare cell analysis for personalized medicine, and prenatal testing services sold to healthcare institutions and laboratories.
  • Relife Dermatology and Aesthetic Medicine Dermatology and aesthetic medicine brand under Menarini, focused on skin health and aesthetic treatments (tagline: 'My skin says how I feel').

Quantifiable outcome

  • 49.8% spleen volume reduction (SVR35) at week 24 with selinexor-ruxolitinib combination vs 28% for ruxolitinib monotherapy in myelofibrosis patients
  • +2 more outcomes

Companies that use Menarini Group

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Menarini Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Menarini Group partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Insilico MedicinecoreStrategic or Co-development Partner · 1 July 2025AI-driven drug discovery collaboration where Insilico Medicine designed MEN2501 (KIF18A inhibitor) using its generative AI engine. Menarini's subsidiary Stemline Therapeutics holds the license. The combined value of agreements exceeds USD 550 million, including milestone payments of USD 3 million (July 2025 after IND approval) and USD 5 million (after first-in-human dosing).
  • ERBCminorStrategic or Co-development Partner · 3 April 2025Strategic partnership to help biopharmaceutical companies transition from research stage to First-In-Human clinical trials, combining preclinical expertise with CMC capabilities for integrated services including non-clinical studies, regulatory-ready data modules, and scalable manufacturing.
  • Karyopharm TherapeuticscoreStrategic or Co-development PartnerCollaboration on selinexor for myelofibrosis treatment. Menarini Group holds global licensing rights for selinexor outside the United States. The Phase 3 SENTRY trial was conducted by Karyopharm and results were presented at EHA 2026 congress, showing statistically significant spleen volume reduction improvement with the selinexor-ruxolitinib combination.
  • NewAmsterdam PharmacoreOEM/ Whitelabel/ Licensing PartnerMenarini Group holds exclusive commercialization rights for obicetrapib (CETP inhibitor) in Europe. NewAmsterdam is developing the drug for hypercholesterolaemia with EMA expected to issue regulatory decision in H2 2026.
  • Stemline TherapeuticscoreOthersWholly-owned subsidiary of Menarini Group focused on bringing transformational oncology treatments to cancer patients. Based in the United States, Stemline commercializes elacestrant (ORSERDU®) and tagraxofusp, and holds licenses for selinexor and MEN2501.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Menarini Group competitors and assessment

Company assessment

Broad incumbents

  • Bayer AG: German-headquartered diversified life sciences group with pharmaceuticals, consumer health, and crop science. Comparable to Menarini in European roots, diversified therapeutic portfolio, and consumer healthcare scale.
  • Roche Holding AG: Swiss-headquartered global pharmaceutical leader with the largest oncology franchise in the industry, complemented by diagnostics. Comparable on oncology pipeline depth and diagnostics business overlap.
  • Merck KGaA: German diversified science and technology company with healthcare, life science, and electronics. Comparable European mid-large pharma with oncology, neurology, and fertility therapeutic areas.
  • GSK plc: UK global biopharma with pharmaceuticals, vaccines, and consumer healthcare. Comparable to Menarini on consumer healthcare (OTC), respiratory, and oncology overlap.
  • Teva Pharmaceutical Industries Ltd. Israel-headquartered global pharmaceutical company with large specialty and generics franchise. Comparable on broad geographic commercial reach and diversified therapeutic portfolio.
  • AstraZeneca PLC: UK-headquartered global biopharmaceutical company with leadership in oncology, cardiometabolic, and respiratory. Comparable on the same oncology and cardiometabolic therapeutic areas that anchor Menarini's recent launches.
  • Sanofi: French global pharmaceutical company with strong European presence, consumer healthcare (OTC), specialty care, and oncology pipeline. Comparable diversified European pharma with comparable revenue scale and therapeutic breadth.

Direct peers

  • Almirall S.A. Spanish privately-listed mid-pharma focused on dermatology and specialty care. Comparable European specialty pharma with overlapping consumer health and derma/aesthetic medicine profile.
  • Chiesi Farmaceutici S.p.A. Italian privately-owned pharmaceutical group operating in respiratory, neonatology, and rare diseases. Comparable privately-held European mid-pharma with focus on specialty therapeutic areas.
  • Recordati S.p.A. Italian-headquartered mid-cap specialty pharmaceutical company with focus on cardiovascular, urology, and rare diseases. Closely comparable to Menarini in European, family-influenced pharma operating model and therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Menarini Group social profiles

Digital presence

Menarini Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Menarini Group leadership team

Management profile

Number of profiles

Profiles3 records

Menarini Group subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Menarini Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Menarini Group M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Menarini Group

What does Menarini Group do?

Menarini Group is a fully integrated privately owned pharmaceutical company that develops, manufactures, and commercializes prescription medicines, consumer healthcare (OTC) products, oncology therapeutics, diagnostics, and dermatology/aesthetic medicine products across more than 130 countries. Its core revenue drivers are prescription pharmaceuticals spanning anti-infectives, cardiometabolic, respiratory, gastrointestinal, pain, men's health, plus a growing oncology franchise centered on elacestrant (ORSERDU®), tagraxofusp, and the licensed products selinexor and obicetrapib. The company also sells professional and advanced diagnostics and prenatal testing through its diagnostics business, and OTC products through its consumer healthcare division.

Is Menarini Group a public or private company?

Menarini Group is a private company. It is classified as family owned and is currently operating.

When was Menarini Group founded?

Menarini Group was founded in 1886. It employs 10,001+ people.

Where is Menarini Group based?

Menarini Group is headquartered in Firenze, Italy, in the Europe region.

How does Menarini Group make money?

Three revenue lines are on record. Pharmaceutical Products are the primary driver. The others are licensing and Royalties and diagnostics.

Who are Menarini Group's main competitors?

Broad incumbents on record are Bayer AG, Roche Holding AG, Merck KGaA, GSK plc, Teva Pharmaceutical Industries Ltd., AstraZeneca PLC and Sanofi. Direct peers are Almirall S.A., Chiesi Farmaceutici S.p.A. and Recordati S.p.A..

Does Menarini Group have an API?

No public API is recorded for Menarini Group.

What industry is Menarini Group in?

Menarini Group's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterMenarini announces first European launch of Ubeslo and EvlarcoMenarini Group announced the first European commercial launch of Ubeslo and Evlarco for primary hypercholesterolemia patients. Both treatments are available and reimbursed in Germany, expanding oral options for patients struggling to reach LDL-C targets.AktienDie Menarini Group und Ryvu Therapeutics geben auf der ASH-Jahrestagung 2026 die ersten klinischen Daten aus der Phase-II-Studie JASPIS-01 zu Dapolsertib (MEN1703, SEL24) bei stark vorbehandelten Patienten mit rezidiviertem/refraktärem aggressivem B-Zell-Menarini, Stemline, and Ryvu will present first clinical data from Phase-II study JASPIS-01 on Dapolsertib for heavily pre-treated patients with relapsed/refractory aggressive B-cell NHL at ASH 2026. The data show clinical efficacy in patients who had, on average, four prior therapy lines, including CAR-T and bispecific antibodies.PR NewswireDie Menarini Group und Ryvu Therapeutics geben auf der ASH-Jahrestagung 2026 die ersten klinischen Daten aus der Phase-II-Studie JASPIS-01 zu Dapolsertib (MEN1703, SEL24) bei stark vorbehandelten PatiMenarini, Stemline, and Ryvu will present first clinical data from the Phase II JASPIS-01 study on dapolsertib at ASH 2026. The data show clinical activity in heavily pretreated patients, with 53% having prior CAR-T and 60% having bispecific antibodies. The results will be presented on December 13, 2026.PR NewswireMenarini Group et Ryvu Therapeutics annoncent les premières données cliniques de l'étude de phase II JASPIS-01 sur le dapolsertib (MEN1703, SEL24)Menarini and Ryvu announced first clinical data of dapolsertib (MEN1703) in phase II JASPIS-01 for relapsed/refractory aggressive B-cell NHL at ASH 2026. The data showed clinical activity in heavily pre-treated patients, with 53% having prior CAR-T and 60% having bispecific antibodies. Results will be presented on December 13, 2026.PR Newswire APACMenarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual MeetingMenarini and Ryvu announced first clinical data from the Phase II JASPIS-01 study of dapolsertib in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, to be presented at ASH 2026. The data showed clinical activity and a manageable safety profile, supporting continued development of the dual PIM/FLT3 inhibitor.AktienMenarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual MeetingMenarini and Ryvu announced first clinical data from the Phase II JASPIS-01 study of dapolsertib in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clinical activity was observed in patients with a median of four prior lines of therapy, including 53% prior CAR-T and 60% prior CD3×CD20 bispecifics. The data will be presented at the 2026 ASH Annual Meeting.PR NewswireMenarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-HodgMenarini and Ryvu announced first clinical data from the Phase II JASPIS-01 study of dapolsertib in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clinical activity was observed in patients with a median of four prior lines of therapy, including 53% who had received CAR-T cell therapy. The data will be presented at ASH 2026.NewswireMenarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual MeetingMenarini and Ryvu announced first clinical data from the Phase II JASPIS-01 study of dapolsertib in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clinical activity was observed in patients with a median of four prior lines of therapy, including 53% who had received CAR-T and 60% who had received CD3×CD20 bispecific antibodies. The data will be presented at the 2026 ASH Annual Meeting.PR NewswireMenarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-HodgMenarini and Ryvu announced first clinical data from the Phase II JASPIS-01 study of dapolsertib in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clinical activity was observed in patients with a median of four prior lines of therapy, including 53% who had received CAR-T cell therapy. The data will be presented at ASH 2026.Nate[PRNewswire] 조지아뮨과 메나리니 그룹, GIM-621 독점 라이선스 및 협력 계약 체결 : 네이트 뉴스Georgiamune and Menarini Group's Stemline Therapeutics signed an exclusive global license and collaboration deal for GIM-621, a first-in-class oral immunotherapy for solid tumors. Georgiamune will receive $45 million upfront, with total deal value up to $1.1 billion plus royalties.